



PATENTS  
VPI/SW/006 FWC DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Roland E. Dolle, et al.  
Application No. : 10/668,475 Confirmation No. : 2933  
Filed : September 22, 2003  
For : 4-PYRIDAZINECARBOXAMIDES AND ESTERS AS  
INTERLEUKIN-1 $\beta$  CONVERTING ENZYME  
INHIBITORS  
Group Art Unit : 1624  
Examiner : Dr. Thomas C. McKenzie, Ph.D.

Palo Alto, CA  
May 12, 2005

**Mail Stop: Amendment**  
Hon. Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

TERMINAL DISCLAIMER UNDER  
37 C.F.R. § 1.321(b) and (c)

Sir:

VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of the Commonwealth of Massachusetts, having an office and place of business at 130 Waverly Street, Cambridge, Massachusetts 02139-4242, represents that it is the assignee of record of the entire right, title and interest, by assignment, of the following:

05/16/2005 SMINASS1 00000011 061075 10668475

01 FC:1814 130.00 DA

United States patent application No. 10/668,475 ("the '475 application"), entitled "4-PYRIDAZINECARBOXAMIDES AND ESTERS AS INTERLEUKIN-1 $\beta$  CONVERTING ENZYME INHIBITORS," filed on September 22, 2003; which application is a divisional of U.S. patent application 08/625,680 ("the '680 application"), filed April 3, 1996, now U.S. Patent 6,624,166, which is a continuation of U.S. patent application 08/452,767, filed May 30, 1995, now abandoned; which is a continuation of U.S. patent application 08/073,914 ("the '914 application"), filed June 8, 1993, now abandoned; and

United States patent application No. 08/444,984 ("the '984 application"), entitled "PYRIDAZINES AS INTERLEUKIN-1 $\beta$  CONVERTING ENZYME INHIBITORS," filed on May 19, 1995, now U.S. Patent 6,121,266 ("the '266 patent"); which is a divisional of the '914 application, now abandoned.

Assignments of the entire right, title and interest in and to the subject matter of the '475 application and the '266 patent were recorded in the United States Patent and Trademark Office:

(1) in the '680 application on March 16, 1998 at Reel/Frame 9067/0001; on March 6, 1998 at Reel/Frame 9440/0948; and on January 26, 1998 at Reel/Frame 8934/0212 (copies enclosed);

(2) in the '984 application on March 16, 1998 at Reel/Frame 9067/0001; on March 6, 1998 at Reel/Frame 9440/0948;

and on January 26, 1998 at Reel/Frame 8934/0212 (copies enclosed); and

(3) in the '914 application on November 25, 1996 at Reel/Frame 8178/0289 and on June 8, 1993 at Reel/Frame 6590/0643 (copies enclosed).

The undersigned, on behalf of VERTEX PHARMACEUTICALS INCORPORATED, hereby disclaims the terminal portion of any patent granted on the '475 application which would extend beyond the expiration date of the '266 patent.

The undersigned, on behalf of VERTEX PHARMACEUTICALS INCORPORATED, agrees that any patent so granted on the '475 application shall be enforceable only for and during such period as the legal title to said patent shall be the same as the legal title to the '266 patent, this agreement to run with any patent granted on the '475 application and to be binding upon the grantee of the patent and its successors and assigns.


The undersigned does not disclaim any terminal portion of any patent granted on the '475 application prior to the full statutory term of the '266 patent, in the event that the '266 patent subsequently (a) expires for failure to pay a maintenance fee, (b) is held unenforceable, (c) is found invalid by a court of competent jurisdiction, (d) is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), (e) has all claims canceled by a reexamination certificate, or (f) is otherwise terminated prior

to expiration of its statutory term, except for the separation of legal title stated above.

The undersigned hereby states and certifies that:

1. The undersigned is an attorney of record in the '475 application and is authorized to act on behalf of assignee corporation in connection with said application; and

2. The above-identified assignment documents have been reviewed and, to the best of the undersigned's and assignee's knowledge and belief, title to the '475 application and the '266 patent is in assignee.

  
James F. Haley, Jr.  
Reg. No. 27,794  
Attorney for Applicants

FISH & NEAVE IP GROUP  
ROPES & GRAY LLP  
Customer No. 1473  
1251 Avenue of the Americas  
New York, New York 10020-1105  
Tel.: (212) 596-9000  
Fax: (212) 596-9090



*Attntas 9/1/98*  
**UNITED STATES DEPARTMENT OF COMMERCE**  
**Patent and Trademark Office**  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

MAY 28, 1998

PTAS



\*100676712A\*

FISH & NEAVE  
JAMES F. HALEY, JR.  
1251 AVENUE OF THE AMERICAS  
NEW YORK, NY 10020

**UNITED STATES PATENT AND TRADEMARK OFFICE**  
**NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT**

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 03/16/1998

REEL/FRAME: 9067/0001

NUMBER OF PAGES: 4

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

SANOFI

DOC DATE: 12/19/1997

ASSIGNEE:

VERTEX PHARMACEUTICALS INCORPORATED  
130 WAVERLY STREET  
CAMBRIDGE, MASSACHUSETTS 02139-4242

SERIAL NUMBER: 08444984

PATENT NUMBER:

FILING DATE: 05/19/1995

ISSUE DATE:

SERIAL NUMBER: 08625680

PATENT NUMBER:

FILING DATE: 04/03/1996

ISSUE DATE:

SERIAL NUMBER: 08440179

PATENT NUMBER: 5756465

FILING DATE: 05/12/1995

ISSUE DATE: 05/26/1998

SERIAL NUMBER: 08748117

PATENT NUMBER:

FILING DATE: 11/12/1996

ISSUE DATE:

**RECEIVED**

JUN 04 1998

FISH & NEAVE - PATENT DEPT.  
REFERRED TO LAD  
NOTED BY

9067/0001 PAGE 2

SERIAL NUMBER: 08248791  
PATENT NUMBER:

FILING DATE: 05/25/1994  
ISSUE DATE:

SERIAL NUMBER: 08597346  
PATENT NUMBER:

FILING DATE: 02/06/1996  
ISSUE DATE:

SERIAL NUMBER: 08559870  
PATENT NUMBER: 5670494

FILING DATE: 11/20/1995  
ISSUE DATE: 09/23/1997

SEDLEY PYNE, PARALEGAL  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS



**UNITED STATES DEPARTMENT OF COMMERCE**  
**Patent and Trademark Office**  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231



\*100676712B\*

AUTHORIZATION TO CHARGE ADDITIONAL FEES TO DEPOSIT ACCOUNT

MAY 28, 1998

TO: OFFICE OF FINANCE  
FROM: ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS  
SUBJECT: DEPOSIT ACCOUNT CHARGE(S)

CHARGE THE DEPOSIT ACCOUNT LISTED BELOW ADDITIONAL FEE(S) AS INDICATED BELOW. AUTHORIZATION TO CHARGE ADDITIONAL FEES HAS BEEN PROVIDED PER THE ATTACHED COVER SHEET, OR BY DIRECT CONTACT WITH THE CUSTOMER.

DEPOSIT ACCOUNT NUMBER: 06-1075  
PROPERTY NUMBER: 08444984

RECORDING FEES:

FEE CODE: 581 AMOUNT: 240

IF YOU HAVE ANY QUESTIONS REGARDING THIS NOTICE, YOU MAY CONTACT THE INDIVIDUAL WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723.

SEDLEY PYNE, PARALEGAL  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS

TRADEMARK SERVICE FEES:

FEE CODE:

RECORDING FIRST MARK	481
RECORDATION SECOND AND SUBSEQUENT MARK IN SAME DOCUMENT	482
LABOR CHARGES FOR SERVICES PER HOURS OR FRACTION THEREOF	484
UNSPECIFIED OTHER SERVICES	485

PATENT SERVICE FEES:

RECORDING EACH PATENT ASSIGNMENT, 581

AGREEMENT, OTHER PAPER, PER PROPERTY  
LABOR CHARGES FOR SERVICES PER HOUR 584  
(\$30) OR FRACTION THEREOF  
UNSPECIFIED OTHER SERVICES 585



04-07-1998

U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

FORM PTO-1595

1-31-92

RI

Docket No. See Attached Appendix

100676712

To the Honorable Commissioner of Patents and Trademarks, please return the attached original documents or copy thereof.

1. Name of conveying party(ies):

Samon  
32-34 rue Marbeuf  
75374 Paris Cedex 08 FRANCE

Additional name(s) of conveying party(ies) attached? [ ] Yes [X] No

3. Nature of Conveyance:

<input checked="" type="checkbox"/> Assignment	<input type="checkbox"/> Merger
<input type="checkbox"/> Security Agreement	<input type="checkbox"/> Change of Name
<input type="checkbox"/> Other	

Execution Date (of Assignment): December 19, 1997  
(of Application):

2. Name and address of receiving party(ies):

Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, MA 02139-4242

Additional name(s) &amp; address(es) attached? [ ] Yes [X] No

4. Application number(s) or patent number(s): See Attached Appendix

09 039657

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s) See Attached Appendix  
Additional numbers attached?B. Patent No.(s) See Attached Appendix  
[ ] Yes [ ] No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Fish & Neave  
Internal Address:Street Address: 1251 Avenue of the AmericasCity: New York State: NY ZIP: 100206. Total number of applications and patents involved: 7 (7)7. Total fee (37 CFR 3.41): .....\$ \$280.00

(Please charge deposit account number.)

8. Deposit account number:

06-1075

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document

JAMES F. HALEY, JR.

Name of Person Signing

Signature

1/22/98

Date

Total number of pages including cover sheet, attachments, and document: 5

OMBNo. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks  
Box Assignments  
Washington, D.C. 20231

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503

1c523 U.S. PTO  
09/039657

03/16/98

09039657

0651-0011

04/02/98 TUCM1  
01 FC5501

**APPENDIX A**  
**UNITED STATES - Patent Applications**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
61859	Dolle et al.	08/444,984 19-May-1995	PYRIDAZINES AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS
61859	Dolle et al.	08/625,680 03-Apr-1996	PYRIDAZINES AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS
63939	Black et al.	08/440,179 12-May-1995	INTERLEUKIN-1-BETA PROTEASE AND INTERLEUKIN-1-BETA PROTEASE INHIBITORS
64322	Dolle et al.	08/748,117 12-Nov-1996	HALOMETHYL AMIDES AS INTERLEUKIN-1-BETA PROTEASE INHIBITORS
66590	Dolle et al.	08/248,791 25-May-1994	PEPTIDIC PHOSPHINYLOXYLMETHYL KETONES AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS
66590	Dolle et al.	08/597,346 06-Feb-1996	PEPTIDIC PHOSPHINYLOXYLMETHYL KETONES AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS
68428	Dolle et al.	08/559,870 20-Nov-1995	N-(PYRIMIDINYL)-ASPARTIC ACID ANALOGS AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS

**ASSIGNMENT OF INVENTION**

THIS ASSIGNMENT effective the 24<sup>th</sup> day of July 1997 between SANOFI, of 32-34 rue Marbeuf, 75374 Paris Cedex 08, France, a société anonyme of France (hereinafter the "Assignor"), who is the owner of the entire title in the United States patent applications set forth in Appendix A and in the inventions covered by said resulting patents; and

VERTEX PHARMACEUTICALS INCORPORATED of 130 Waverly Street, Cambridge, Massachusetts 02139-4242, a corporation of the Commonwealth of Massachusetts (hereinafter the "Assignee"), who wants to acquire the entire title of Assignor in the aforesaid patent applications and the inventions covered thereby.

THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor does hereby assign unto Assignee its entire title in said patent applications, and all reissues, divisions and extensions thereof and to any Letters Patent which have or may issue based thereon, all of which are encompassed herein by the term "Patents", including all claims for damage for past infringement thereof; the same to be held and enjoyed by Assignee, its successors, and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment and sale not been made.

Assignor also agrees that it will, at Assignee's request, render such lawful cooperation and assistance as may be necessary for the proper maintenance and enforcement of said Patents, provided, however, that Assignor may condition its compliance with such a request on Assignee's agreement to pay Assignor reasonable out-of-pocket expenses in connection therewith.

This document shall be construed, interpreted and applied in accordance with the laws of the State of New York.

IN WITNESS THEREOF, the parties have caused their respective corporate names to be affixed hereto and this instrument to be signed by their duly authorized officers as of the day and year written below.

IN WITNESS WHEREOF, I have hereunto set hand and seal this

19<sup>th</sup> day of December, 1997

**sanofi**  
32-34 rue Marbeuf  
75008 PARIS

Sole Societ: 32-34, rue Marbeuf - 75008 Paris  
Rue Paris B 732059 332

(Corporate Seal)

SANOFI

By John M. Spinnato  
JOHN M. SPINNATO  
Attorney-in-Fact

Witnessed by: Anita Beldjilali  
Name: Anita Beldjilali  
Title: Executive Assistant

IN WITNESS WHEREOF, I have hereunto set hand and seal this.

9<sup>th</sup> day of January, 1998

VERTEX PHARMACEUTICALS  
INCORPORATED

(Corporate Seal)

By Joshua S. Boger  
JOSHUA S. BOGER  
President and Chief Executive Officer

Witnessed by: Sarah P. Cecil  
Name: SARAH P. CECIL  
Title: Corporate Attorney



201.99  
UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

JANUARY 22, 1999

PTAS

FISH & NEAVE  
JAMES F. HALEY, JR.  
1251 AVENUE OF THE AMERICAS  
NEW YORK, NY 10020



\*100828387A\*

UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 03/06/1998

REEL/FRAME: 9440/0948  
NUMBER OF PAGES: 4

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:  
SANOFI

DOC DATE: 12/19/1997

ASSIGNEE:  
VERTEX PHARMACEUTICALS  
INCORPORATED  
130 WAVERLY STREET  
CAMBRIDGE, MASSACHUSETTS 02139-4242

SERIAL NUMBER: 08444984  
PATENT NUMBER:

FILING DATE: 05/19/1995  
ISSUE DATE:

SERIAL NUMBER: 08685680  
PATENT NUMBER:

FILING DATE: 07/24/1996  
ISSUE DATE:

SERIAL NUMBER: 08440179  
PATENT NUMBER: 5756465

FILING DATE: 05/12/1995  
ISSUE DATE: 05/26/1998

SERIAL NUMBER: 08748117  
PATENT NUMBER: 5834514

FILING DATE: 11/12/1996  
ISSUE DATE: 11/10/1998

RECEIVED

JAN 28 1999

FISH & NEAVE - PATENT DEPT.  
REFERRED TO SGD/LAD/SDM  
NOTED BY \_\_\_\_\_

9440/0948 PAGE 2

SERIAL NUMBER: 08248791  
PATENT NUMBER:

SERIAL NUMBER: 08597346  
PATENT NUMBER: 5843905

SERIAL NUMBER: 08559870  
PATENT NUMBER: 5670494

FILING DATE: 05/25/1994  
ISSUE DATE:

FILING DATE: 02/06/1996  
ISSUE DATE: 12/01/1998

FILING DATE: 11/20/1995  
ISSUE DATE: 09/23/1997

ANTOINE ROYALE, EXAMINER  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS



**UNITED STATES DEPARTMENT OF COMMERCE**  
**Patent and Trademark Office**  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231



\*100828387B\*

**AUTHORIZATION TO CHARGE ADDITIONAL FEES TO DEPOSIT ACCOUNT**

**JANUARY 22, 1999**

**TO: OFFICE OF FINANCE**  
**FROM: ASSIGNMENT DIVISION**  
**OFFICE OF PUBLIC RECORDS**  
**SUBJECT: DEPOSIT ACCOUNT CHARGE(S)**

CHARGE THE DEPOSIT ACCOUNT LISTED BELOW ADDITIONAL FEE(S) AS INDICATED BELOW. AUTHORIZATION TO CHARGE ADDITIONAL FEES HAS BEEN PROVIDED PER THE ATTACHED COVER SHEET, OR BY DIRECT CONTACT WITH THE CUSTOMER.

DEPOSIT ACCOUNT NUMBER: 061075  
PROPERTY NUMBER: 08444984

**RECORDING FEES:**

FEE CODE: 581 AMOUNT: 280

IF YOU HAVE ANY QUESTIONS REGARDING THIS NOTICE, YOU MAY CONTACT THE INDIVIDUAL WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723.

ANTOINE ROYALE, EXAMINER  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS

TRADEMARK SERVICE FEES:	FEE CODE:
RECORDING FIRST MARK	481
RECORDATION SECOND AND SUBSEQUENT MARK IN SAME DOCUMENT	482
LABOR CHARGES FOR SERVICES PER HOURS OR FRACTION THEREOF	484
UNSPECIFIED OTHER SERVICES	485

**PATENT SERVICE FEES:**

RECORDING EACH PATENT ASSIGNMENT, 581

AGREEMENT, OTHER PAPER, PER PROPERTY  
LABOR CHARGES FOR SERVICES PER HOUR  
(\$30) OR FRACTION THEREOF  
UNSPECIFIED OTHER SERVICES

584

585



D\$

FORM PTO-1595

3-31-92

Docket No. See Attached Appendix

MAR 12 1998

09-14-1998



100828387

DEPARTMENT OF COMMERCE  
Patent and Trademark Office

To the Honorable Commissioner of Patents and Trademarks at

1. Name of conveying party(ies)

Sanofi

32-34 rue Marbeuf

75374 Paris Cedex 08 FRANCE

Additional name(s) of conveying party(ies) attached? [ ] Yes [X] No

3. Nature of Conveyance:

[X] Assignment

[ ] Merger

[ ] Security Agreement

[ ] Change of Name

[ ] Other

Execution Date (of Assignment): December 19, 1997

(of Application):

2. Name and address of receiving party(ies)

Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, MA 02139-4242

RECEIVED

MAR - 6 1998

GROUP 2200

Additional name(s) & address(es) attached? [ ] Yes [X] No

4. Application number(s) or patent number(s): See Attached Appendix

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

See Attached Appendix

Additional numbers attached?

B. Patent No.(s) See Attached Appendix

[ ] Yes

[ ] No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Fish & Neave

Internal Address:

Street Address: 1251 Avenue of the Americas

City: New York State: NY ZIP: 10020

6. Total number of applications and patents involved: [7]

7. Total fee (37 CFR 3.41): .....\$ \$280.00

( Please charge deposit account number: )

8. Deposit account number:

06-1075

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document

JAMES F. HALEY, JR.

Name of Person Signing

Signature

Date

Total number of pages including cover sheet, attachments, and document: [ 5 ]

OMBNo. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks

Box Assignments

Washington, D.C. 20231

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project. (0651-0011), Washington, D.C. 20503

MRD 3-6-98

**APPENDIX A**  
**UNITED STATES - Patent Applications**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
61859	Dolle et al.	08/444,984 19-May-1995	PYRIDAZINES AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS
61859	Dolle et al.	08/625,680 03-Apr-1996	PYRIDAZINES AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS
63939	Black et al.	08/440,179 12-May-1995	INTERLEUKIN-1-BETA PROTEASE AND INTERLEUKIN-1-BETA PROTEASE INHIBITORS
64322	Dolle et al.	08/748,117 12-Nov-1996	HALOMETHYL AMIDES AS INTERLEUKIN-1-BETA PROTEASE INHIBITORS
66590	Dolle et al.	08/248,791 25-May-1994	PEPTIDIC PHOSPHINYLOXYLMETHYL KETONES AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS
66590	Dolle et al.	08/597,346 06-Feb-1996	PEPTIDIC PHOSPHINYLOXYLMETHYL KETONES AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS
68428	Dolle et al.	08/559,870 20-Nov-1995	N-(PYRIMIDINYL)-ASPARTIC ACID ANALOGS AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS

**ASSIGNMENT OF INVENTION**

THIS ASSIGNMENT effective the 24<sup>th</sup> day of July 1997 between SANOFI, of 32-34 rue Marbeuf, 75374 Paris Cedex 08, France, a société anonyme of France (hereinafter the "Assignor"), who is the owner of the entire title in the United States patent applications set forth in Appendix A and in the inventions covered by said resulting patents; and

VERTEX PHARMACEUTICALS INCORPORATED of 130 Waverly Street, Cambridge, Massachusetts 02139-4242, a corporation of the Commonwealth of Massachusetts (hereinafter the "Assignee"), who wants to acquire the entire title of Assignor in the aforesaid patent applications and the inventions covered thereby.

THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor does hereby assign unto Assignee its entire title in said patent applications, and all reissues, divisions and extensions thereof and to any Letters Patent which have or may issue based thereon, all of which are encompassed herein by the term "Patents", including all claims for damage for past infringement thereof, the same to be held and enjoyed by Assignee, its successors, and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment and sale not been made.

Assignor also agrees that it will, at Assignee's request, render such lawful cooperation and assistance as may be necessary for the proper maintenance and enforcement of said Patents, provided, however, that Assignor may condition its compliance with such a request on Assignee's agreement to pay Assignor reasonable out-of-pocket expenses in connection therewith.

This document shall be construed, interpreted and applied in accordance with the laws of the State of New York.

IN WITNESS THEREOF, the parties have caused their respective corporate names to be affixed hereto and this instrument to be signed by their duly authorized officers as of the day and year written below.

IN WITNESS WHEREOF, I have hereunto set hand and seal this

19<sup>th</sup> day of December, 1997

**sanofi**  
32-34 rue Marbeuf  
75008 PARIS  
Siège Social: 32-34, rue Marbeuf - 75008 Paris  
Rue Paris 8 732059 332  
(Corporate Seal)

SANOFI

By John M. Spinnato  
JOHN M. SPINNATO  
Attorney-in-Fact

Witnessed by: Anita Beldjilali  
Name: Anita Beldjilali  
Title: Executive Assistant

IN WITNESS WHEREOF, I have hereunto set hand and seal this


9<sup>th</sup> day of January, 1997<sup>8</sup>

(Corporate Seal)

VERTEX PHARMACEUTICALS  
INCORPORATED

By Joshua S. Boger  
JOSHUA S. BOGER  
President and Chief Executive Officer

Witnessed by: Sarah P. Cecil  
Name: SARAH P. CECIL  
Title: Corporate Attorney



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

MARCH 19, 1998

FISH & NEAVE  
JAMES F. HALEY, JR.  
1251 AVENUE OF THE AMERICAS  
NEW YORK, NY 10020

PTAS  
**RECEIVED**



\*100628196A\*

MAR 26 1998

FISH & NEAVE - PATENT DEF  
REFERRED TO LAD

UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231.

RECORDATION DATE: 01/26/1998

REEL/FRAME: 8934/0212  
NUMBER OF PAGES: 4

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:  
SANOFI

DOC DATE: 12/19/1997

ASSIGNEE:  
VERTEX PHARMACEUTICALS INCORPORATED  
130 WAVERLY STREET  
CAMBRIDGE, MASSACHUSETTS 02139-4242

SERIAL NUMBER: 08444984  
PATENT NUMBER:

FILING DATE: 05/19/1995  
ISSUE DATE:

SERIAL NUMBER: 08625680  
PATENT NUMBER:

FILING DATE: 04/03/1996  
ISSUE DATE:

SERIAL NUMBER: 08440179  
PATENT NUMBER:

FILING DATE: 05/12/1995  
ISSUE DATE:

SERIAL NUMBER: 08748117  
PATENT NUMBER:

FILING DATE: 11/12/1996  
ISSUE DATE:

8934/0212 PAGE 2

SERIAL NUMBER: 08248791  
PATENT NUMBER:

FILING DATE: 05/25/1994  
ISSUE DATE:

SERIAL NUMBER: 08597346  
PATENT NUMBER:

FILING DATE: 02/06/1996  
ISSUE DATE:

SERIAL NUMBER: 08559870  
PATENT NUMBER: 5670494

FILING DATE: 11/20/1995  
ISSUE DATE: 09/23/1997

ANNIE HARRELL, PARALEGAL  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS

02-09-1998

FORM PTO-1595

1-31-92

RECORD

DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Docket No. See Attached Appendix

100628196

To the Honorable Commissioner of Patents and Trademarks. Please record the document or copy thereof. JAN 23 1998

1. Name of conveying party(ies):

Sanofi

32-34 rue Marbeuf

75374 Paris Cedex 08 FRANCE

Additional name(s) of conveying party(ies) attached? [ ] yes [X] no

3. Nature of Conveyance:

☒ Assignment☐ Merger☐ Security Agreement☐ Change of Name☐ Other

Execution Date (of Assignment): December 19, 1997

(of Application):

2. Name and address of receiving party(ies):

Vertex Pharmaceuticals Incorporated

130 Waverly Street

Cambridge, MA 02139-4242

Additional name(s) &amp; address(es) attached? [ ] Yes [X] No

4. Application number(s) or patent number(s): See Attached Appendix

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

See Attached Appendix

Additional numbers attached?

B. Patent No.(s) See Attached Appendix

[ ] Yes

[ ] No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Fish &amp; Neave

Internal Address:

Street Address: 1251 Avenue of the Americas

City: New York State: NY ZIP 10020

6. Total number of applications and patents involved: [ 7 ]

7. Total fee (37 CFR 3.41): \$ 280.00

( Please charge deposit account number: )

8. Deposit account number:

06-1075

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document

JAMES F. HALEY, JR.

Name of Person Signing

Signature

Date

Total number of pages including cover sheet, attachments, and document: [ 5 ]

OMBNo. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

02/06/1998 VERBOM 00000256 DAN:061075 0824873 Commissioner of Patents and Trademarks  
01 FC:581 280.00 CH Box Assignments  
Washington, D.C. 20231

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project. (0651-0011), Washington, D.C. 20503

**APPENDIX A**  
**UNITED STATES - Patent Applications**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
61859	Dolle et al.	08/444,984 19-May-1995	PYRIDAZINES AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS
61859	Dolle et al.	08/625,680 03-Apr-1996	PYRIDAZINES AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS
63939	Black et al.	08/440,179 12-May-1995	INTERLEUKIN-1-BETA PROTEASE AND INTERLEUKIN-1-BETA PROTEASE INHIBITORS
64322	Dolle et al.	08/748,117 12-Nov-1996	HALOMETHYL AMIDES AS INTERLEUKIN-1-BETA PROTEASE INHIBITORS
66590	Dolle et al.	08/248,791 25-May-1994	PEPTIDIC PHOSPHINYLOXYLMETHYL KETONES AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS
66590	Dolle et al.	08/597,346 06-Feb-1996	PEPTIDIC PHOSPHINYLOXYLMETHYL KETONES AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS
68428	Dolle et al.	08/559,870 20-Nov-1995	N-(PYRIMIDINYL)-ASPARTIC ACID ANALOGS AS INTERLEUKIN-1-BETA CONVERTING ENZYME INHIBITORS



ASSIGNMENT OF INVENTION

THIS ASSIGNMENT effective the 24<sup>th</sup> day of July 1997 between SANOFI, of 32-34 rue Marbeuf, 75374 Paris Cedex 08, France, a société anonyme of France (hereinafter the "Assignor"), who is the owner of the entire title in the United States patent applications set forth in Appendix A and in the inventions covered by said resulting patents; and

VERTEX PHARMACEUTICALS INCORPORATED of 130 Waverly Street, Cambridge, Massachusetts 02139-4242, a corporation of the Commonwealth of Massachusetts (hereinafter the "Assignee"), who wants to acquire the entire title of Assignor in the aforesaid patent applications and the inventions covered thereby.

THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor does hereby assign unto Assignee its entire title in said patent applications, and all reissues, divisions and extensions thereof and to any Letters Patent which have or may issue based thereon, all of which are encompassed herein by the term "Patents", including all claims for damage for past infringement thereof; the same to be held and enjoyed by Assignee, its successors, and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment and sale not been made.

Assignor also agrees that it will, at Assignee's request, render such lawful cooperation and assistance as may be necessary for the proper maintenance and enforcement of said Patents, provided, however, that Assignor may condition its compliance with such a request on Assignee's agreement to pay Assignor reasonable out-of-pocket expenses in connection therewith.

This document shall be construed, interpreted and applied in accordance with the laws of the State of New York.

IN WITNESS THEREOF, the parties have caused their respective corporate names to be affixed hereto and this instrument to be signed by their duly authorized officers as of the day and year written below.

IN WITNESS WHEREOF, I have hereunto set hand and seal this

19<sup>th</sup> day of December, 1997

**sanofi**  
**32-34 rue Marbeuf**  
**75008 PARIS**  
Siege Social: 32-34, rue Marbeuf - 75008 Paris  
Rou Paris B 732059 332  
(Corporate Seal)

SANOFI

By *John M. Spinnato*  
**JOHN M. SPINNATO**  
Attorney-in-Fact

Witnessed by: *Anita Beldjilali*  
Name: Anita Beldjilali  
Title: Executive Assistant

IN WITNESS WHEREOF, I have hereunto set hand and seal this


9<sup>th</sup> day of January, 1998

(Corporate Seal)

**VERTEX PHARMACEUTICALS  
INCORPORATED**

By *Joshua S. Boger*  
**JOSHUA S. BOGER**  
President and Chief Executive Officer

Witnessed by: *Sarah P. Cecil*  
Name: SARAH P. CECIL  
Title: Corporate Attorney



**UNITED STATES DEPARTMENT OF COMMERCE**  
**Patent and Trademark Office**  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

DECEMBER 17, 1996

PTAS

SANOFI WINTHROP, INC.  
WILLIAM J. DAVIS  
PATENT DEPARTMENT  
9 GREAT VALLEY PKWY  
MALVERN, PA 19355

96-12-24A09:41 RCVD

**UNITED STATES PATENT AND TRADEMARK OFFICE**  
**NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT**

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231.

RECORDATION DATE: 11/25/1996

REEL/FRAME: 8178/0289  
NUMBER OF PAGES: 25

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

**ASSIGNOR:**

STERLING WINTHROP, INC.

DOC DATE: 02/27/1996

**ASSIGNEE:**

SANOFI S.A.  
32-34, RUE MARBEUF  
75374 PARIS CEDEX 08, FRANCE

SERIAL NUMBER: 08320013  
PATENT NUMBER: 5434159

FILING DATE: 10/07/1994  
ISSUE DATE: 07/18/1995

SERIAL NUMBER: 07793035  
PATENT NUMBER:

FILING DATE: 11/15/1991  
ISSUE DATE:

SERIAL NUMBER: 07912949  
PATENT NUMBER: 5378803

FILING DATE: 07/10/1992  
ISSUE DATE: 01/03/1995

SERIAL NUMBER: 07941281  
PATENT NUMBER:

FILING DATE: 09/04/1992  
ISSUE DATE:

11-25-1996

ARO 11/25/96

FORM PTO-1595

1-31-92

Docket No. See Attached App:



100311232

U.S. DEPARTMENT OF COMMERCE

ET

Patent and Trademark Office

581-13,560

To the Honorable Commissioner of Patents and Trademarks

attached original documents or copy thereof.

1. Name of conveying party(ies):

med  
11/25/96

STERLING Winthrop Inc.

Additional name(s) of conveying party(ies) attached? [ ] Yes [X] No

3. Nature of Conveyance:

[X] Assignment [ ] Merger  
[ ] Security Agreement [ ] Change of Name  
[ ] Other

Execution Date (of Assignment): February 27, 1996  
(of Application):

2. Name and address of receiving party(ies):

11/18, 857

Sanofi S.A.  
32-34, Rue Marbeuf  
75374 Paris Cedex 08  
France

Additional name(s) & address(es) attached? [ ] Yes [X] No

4. Application number(s) or patent number(s): See Attached Appendices

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

See Attached Appendices

B. Patent No.(s): See Attached Appendices

Additional numbers attached?

[ ] Yes

[ ] No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Sanofi Winthrop, Inc.  
Internal Address: Patent Department  
William J. Davis

Street Address: 9 Grant Valley Hwy

City: Marlton State: PA ZIP: 19355

6. Total number of applications and patents involved: [ 339 ]

7. Total fee (37 CFR 3.41): .....\$ 13,560.00

Enclosed is a check in the amount of \$13,560.00

8. Charge any additional fees or credit overpayments to Deposit Account No. 19-0091

581-13,560 E

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document

WILLIAM J. DAVIS

Name of Person Signing

William J. Davis

Signature

22 November 1996

Date

Total number of pages including cover sheet, attachments, and document: [ 26 ]

OMB No. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks  
Box Assignments  
Washington, D.C. 20231

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project. (0651-0011), Washington, D.C. 20503

ASSIGNMENT OF INVENTION

This Assignment effective October 1, 1994, between STERLING WINTHROP INC. (WHICH CHANGED ITS NAME FROM STERLING DRUG INC., BY A CERTIFICATE OF AMENDMENT, DATED 18 SEPTEMBER 1991), of 90 Park Avenue, New York, New York 10016, United States of America, a corporation of the State of Delaware (hereinafter the "Assignor"), who is the owner of the entire title in the United States patent applications set forth in Appendix A and in the inventions covered by said resulting patents; and

SANOFI, of 32-34 Rue Marbeuf, 75374 Paris Cedex 08, France, a corporation of the Country of France (hereinafter the "Assignee"), who wants to acquire the entire title of Assignor in the aforesaid patent applications and the inventions covered thereby.

THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor does hereby assign unto Assignee its entire title in said patent applications, and all reissues, divisions and extensions thereof and to any Letters Patent which have or may issue based thereon, all of which are encompassed herein by the term "Patents", including all claims for damage for past infringement thereof; the same to be held and enjoyed by Assignee, its successors, and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment and sale not been made.

Assignor also agrees that it will, at Assignee's request, render such lawful cooperation and assistance as may be necessary for the proper maintenance and enforcement of said Patents, provided, however, that Assignor may condition its compliance with such a request on Assignee's agreement to pay Assignor reasonable out-of-pocket expenses in connection therewith.

This document shall be construed, interpreted and applied in accordance with the laws of the State of New York.

In WITNESS THEREOF, the parties have caused their respective corporate names to be affixed hereto and this instrument to be signed by their duly authorized officers as of the day and year written below.

IN WITNESS WHEREOF, I have hereunto set hand and seal this

30 day of OCTOBER, 1995

STERLING WINTHROP INC.

By Melvyn A. Silver

(Corporate Seal)

Name: Melvyn A. Silver  
Title: Assistant Secretary  
Sterling Winthrop Inc.

Witnessed by: Marilyn M. Feltz

IN WITNESS WHEREOF, I have hereunto set hand and seal this

14 day of February, 1996

**sanofi**  
32-34, rue Marbeuf  
75008 PARIS

SANOFI

Edge Societ : 32-34, rue Marbeuf - 75008 PARIS  
RCS PARIS 8 732 058 332

(Corporate Seal)

By Gilles Mauduit  
27/2/96  
Gilles Mauduit  
Counsel

Witnessed by: Dominique Mollero  
Dominique MOLLERO  
9/10/96

**APPENDIX A**  
**UNITED STATES - Patent Applications**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
65403	Dehaven-Hudkins et al	08/ 320013 07Oct94	6,11-cyclyl-1,2,3,4,5,6,11,11A- Octahydrobenzoyl-Quinolones And Compositions And Method of Use Thereof
55381	Dunlap et al	07/ 793035 15Nov91	Saccharin Derivative Proteolytic Enzyme Inhibitors
64821	Morgan, B.A.	07/ 912949 10Jul92	Azole-Fused Peptides and Processes for Preparation Thereof
61887	Morgan, B.A.	07/ 941281 04Sep92	N-Terminal-Marked Peptides Immobilized on Glass Beads and Method of Preparation Thereof
63951	Mallamo, J.	07/ 982922 30Nov92	4-Phenylpiperidine Agents for Treating CNS Disorders
65454	Diana, G.	07/ 998498 30Dec92	Phenoxy- and Phenoxyalkyl-Piperidines as Antiviral Agents
62348	Seoane et al	08/ 019955 19Feb93	Nonpeptide Bradykinin Antagonists
61784	Delecki et al	08/ 040326 30Mar93	Acyclic Nucleoside Analogs and Oligonucleotide Sequences Containing Them
61786	Cook et al	08/ 040158 30Mar93	7-deazapurine Modified Oligonucleotides
60933	Chaturvedula, P.	08/ 040826 31Mar93	Oligonucleotide With Amide Linkages Replacing Phosphodiester Linkages
61881	Saha, A.K.	08/ 040750 31Mar93	Novel 5' Substituted Nucleosides And Oligomers Produced Therefrom
62389	Weis et al	08/ 041310 31Mar93	Bifunctional Nucleosides, Oligomers Thereof and Methods of Making and Using the Same
62036	Dolle et al	08/ 048982 16Apr93	Calpain Inhibitors For The Treatment Of Neurodegenerative Diseases
61860	Dolle et al	08/ 054122 26Apr93	Novel Quinolone Carboxamide Calpain Inhibitors

**APPENDIX A**  
**UNITED STATES - Patent Applications**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
62040	Dolle et al	08/ 055051 29Apr93	Peptide Analogs As Irreversible Interleukin-1 Beta Protease Inhibitors
62754	Dolle et al	08/ 060197 07May93	Peptidic Ketones As Interleukin-1 Beta Converting Enzyme Inhibitors
55381	Dunlap et al	08/ 067637 24May93	Use of Saccharin Derivatives As Proteolytic Enzyme Inhibitors (As Amended)
64102	Hlasta et al	08/ 066805 25May93	Saccharin Derivative Proteolytic Enzyme Inhibitors
66590	Dolle et al	08/ 073219 04Jun93	Peptidic Phosphinyloxymethyl Ketones As Interleukin-1 Beta-Converting Enzyme Inhibitors
61859	Dolle et al	08/ 073914 08Jun93	Pyridazines As Interleukin-1 Beta Converting Enzyme Inhibitors
56529	Washburn et al	08/ 080546 24Jun93	3,4-Disubstituted Anilines - Immunomodulating Agents
62005	Dunlap et al	08/ 109411 19Aug93	Novel 2-Saccharinylmethyl Heterocyclic Carboxylates Useful as Proteolytic Enzyme Inhibitors
62018	Latimer et al	08/ 109849 20Aug93	Novel 2-Saccharinylmethyl Aryl and Aryloxy Acetates Useful as Proteolytic Enzyme Inhibitors and Compositions and Method of Use Thereof
55381	Dunlap et al	08/ 113508 27Aug93	Saccharin Derivative Proteolytic Enzyme Inhibitors
62557	Weis et al	08/ 114717 31Aug93	Nuclease Resistant Compounds
61848	Dunlap et al	08/ 116416 03Sep93	Novel 2-Saccharinylmethyl Aryl Carboxylates Useful as Proteolytic Enzyme Inhibitors and Compositions and Method of Use Thereof
61742	DeHaven-Hudkins et al	08/ 122039 14Sep93	12-Hetero Substituted 6,11-Ethano-6,11-Dihydrobenzo Quinolizinium Salts And Compositions And Method of Use Thereof
65406	Dehaven-Hudkins et al	08/ 121810 14Sep93	Substituted 6,11-Ethano-6,11-Dihydrobenzoyl Quinolizinium Salts and Compositions and Method of Use Thereof



**APPENDIX A**  
**UNITED STATES - Patent Applications**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
65407	Dehaven-Hudkins et al	08/ 121626 14Sep93	6,11- Substituted -6,11-Dihydrobenzoyl Quinolizinium Salts and Compositions and Method of Use Thereof
63991	Snow et al	08/ 153553 16Nov93	Vinyl Sulfone Coupling of Polyoxyalkylenes to Proteins
61823	Bacon et al	08/ 159158 30Nov93	Novel 6-Heterocyllyl Pyrazolo Y3, 4-D Pyrimidin-4-Ones and Compositions and Method of Use Thereof
61346	Phillips et al	08/ 178205 05Jan94	Lyophilized Polyethylene Oxide Modified Protein and Polypeptide Complexes With Cyclodextrin
63743	Desai, R.	08/ 192914 07Feb94	2-(2,3,5,6-Tetrafluoro-4-Pyridyl)-1,2- Benzoisothiazol-3(2H)-One 1,1,-Dioxides And Compositions And Method of Use Thereof
68349	Gowravaram et al	08/ 201837 25Feb94	Hydroxamic Acid Derivatives, Process For Their Preparation and Use Thereof
63939	Black et al	08/ 203716 28Feb94	Interleukin-1 Beta Protease and Interleukin-1 Beta Protease Inhibitors
62557	Weis et al	08/ 205335 03Mar94	Compounds and Methods For Inhibiting Gene Expression
63152	Washburn et al	08/ 208396 08Mar94	3,4-disubstituted Phenols - Immunomodulating Agents
64304	D'ambra, T.E.	08/ 213777 16Mar94	3-Arylcarbonyl-1-(C-Attached-N-Heteryl)-1H- Indoles
60934	Miller at al	08/ 216989 23Mar94	Thioxanthenone Antitumor Agents
68428	Dolle et al	08/ 221712 31Mar94	N-(Pyrimidinyl)-Aspartic Acid Analogs As Interleukin-1 Beta Converting Enzyme Inhibitors
64322	Dolle et al	08/ 236425 29Apr94	Halomethyl Amides As Interleukin-1Beta Protease Inhibitors

**APPENDIX A**  
**UNITED STATES - Patent Applications**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
66588	Dolle et al	08/ 237920 29Apr94	Alpha-Heteroaryloxymethyl Ketones As Interleukin-1 Beta Converting Enzyme Inhibitors
66593	Aldous et al	08/ 242508 13May94	Therapeutic Phenoxyalkylheterocycles
67931	Aldous et al	08/ 242752 13May94	Therapeutic Phenoxyalkylazoles and Phenoxyalkylazines
67932	Aldous et al	08/ 242529 13May94	Thiadiazoles And Their Use As Antipicornaviral Agents
67979	Aldous et al	08/ 242528 13May94	Therapeutic Phenoxyalkylpyridazines and Intermediates Therefor
62281	Snow et al	08/ 245999 19May94	Low Diol Polyalkylene Oxide Biologically Active Proteinaceous Substances
66590	Dolle et al	08/ 248791 25May94	Peptidic Phosphinyloxymethyl Ketones As Interleukin-1 Beat-Converting Enzyme Inhibitors
60883	Johnson et al	08/ 250995 31May94	Aryl-Fused and Hetaryl-Fused-2,4-Diazepine And 2,4-Diazocine Antiarrhythmic Agents
68853	Dolle et al	08/ 255276 08Jun94	Fused Bicyclic Lactams As Interleukin-1Beta Converting Enzyme Inhibitors
61735	Rubin et al	08/ 259593 14Jun94	Lactam Inhibitors of Cholesterol Esterase
64102	Hlasta et al	08/ 263643 22Jun94	Saccharin Derivative Proteolytic Enzyme Inhibitors
55381	Dunlap et al	08/ 270964 05Jul94	Novel Saccharin Derivatives Useful As Proteolytic Enzyme Inhibitors And Compositions And Method of Use Thereof
65404	DeHaven-Hudkins et al	08/ 283317 29Jul94	Substituted 6,11-Ethano-6,11-Dihydrobenzoyl-Quinolizinium Salts And Compositions and Method of Use Thereof
67875	Dority et al	08/ 283319 29Jul94	Substituted Heterocyclylisoquinolinium Salts And Compositions And Method of Use Thereof

**APPENDIX A**  
**UNITED STATES - Patent Applications**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
70490	Dolle et al	08/ 284861 02Aug94	Azaaspartic Acid Analogs As Interleukin-1Beta Converting Enzyme Inhibitors
62018	Latimer et al	08/ 287372 08Aug94	Novel 2-Saccharinylmethyl Aryl and Aryloxy Acetates Useful as Proteolytic Enzyme Inhibitors and Compositions and Method of Use Thereof
58259	Na et al	08/ 287757 09Aug94	Buffered Formulations of PEG-SOD
62005	Dunlap et al	08/ 287681 09Aug94	Novel 2-Saccharinylmethyl Heterocyclic Carboxylates Useful as Proteolytic Enzyme Inhibitors and Compositions and Method of Use Thereof
55381	Dunlap et al	08/ 289113 11Aug94	Saccharin Derivative Proteolytic Enzyme Inhibitors
68005	Aldous et al	08/ 312724 27Sep94	Antipicornaviral Agents
60883	Johnson et al	08/ 308893 29Sep94	Aryl-Fused and Hetaryl-Fused-2,4-Diazepine And 2,4-Diazocine Antiarrhythmic Agents
63987	Bradley et al	07/ 119763 12Nov87	Human IL-4
62308	Diana et al	08/ 131050 01Oct93	1,2,4-Oxadizolyl-Phenoxyalkylisoxazoles And Their Use As Antiviral Agents
63939	Black et al	07/ 736837 29Jul91	Interleukin-1 Beta Protease and Interleukin-1 Beta Protease Inhibitors
63939	Black et al	08/ 152950 12Nov93	Interleukin-1 Beta Protease and Interleukin-1 Beta Protease Inhibitors

**ASSIGNMENT OF INVENTION**

This Assignment is effective the 1st day of October, 1994, between **STERLING WINTHROP INC. (WHICH CHANGED ITS NAME FROM STERLING DRUG INC., BY A CERTIFICATE OF AMENDMENT, DATED 18 SEPTEMBER 1991)**, of 90 Park Avenue, New York, New York 10016, United States of America, a corporation of the State of Delaware (hereinafter the "Assignor"), who is the owner of the entire title in the United States patents set forth in Appendix A and in the inventions covered by said patents; and

**SANOFI**, of 32-34 Rue Marbeuf, 75374 Paris Cedex 08, France, a corporation of the Country of France (hereinafter the "Assignee"), who wants to acquire the entire title of Assignor in the aforesaid patents and the inventions covered thereby.

**THEREFORE**, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor does hereby assign unto Assignee its entire title in said patents, and all reissues, divisions and extensions thereof and to any Letters Patent which have or may issue based thereon, all of which are encompassed herein by the term "Patents", including all claims for damage for past infringement thereof; the same to be held and enjoyed by Assignee, its successors, and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment and sale not been made.

Assignor also agrees that it will, at Assignee's request, render such lawful cooperation and assistance as may be necessary for the proper maintenance and enforcement of said patents, provided, however, that Assignor may condition its compliance with such a request on Assignee's agreement to pay Assignor reasonable out-of-pocket expenses in connection therewith.

This document shall be construed, interpreted and applied in accordance with the laws of the State of New York.

In WITNESS THEREOF, the parties have caused their respective corporate names to be affixed hereto and this instrument to be signed by their duly authorized officers as of the day and year written below.

IN WITNESS WHEREOF, I have hereunto set hand and seal this

30 day of OCTOBER, 1995

STERLING WINTHROP INC.

(Corporate Seal)

By Melvyn A. Silver

Name: Melvyn A. Silver  
Title: Assistant Secretary  
Sterling Winthrop Inc.

Witnessed by: Mary A. Laurino

IN WITNESS WHEREOF, I have hereunto set hand and seal this

27 day of February, 1996

**sanofi**  
32-34, rue Marbeuf  
75008 PARIS

SANOFI

(Corporate Seal) Société : 32-34, rue Marbeuf - 75008 PARIS  
RCS PARIS 8 732 069 332

By Gilles Mauduit  
27/2/96

Witnessed by: Dominique MOLLERO  
Dominique MOLLERO  
27/02/96

**APPENDIX A**  
**UNITED STATES - Patents**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
71363	Pilling et al	5,053,405 01Oct91	Antiandrogenic Sulfonylsteroidthiazaoles
61223	Mickle et al	5,080,886 14Jan92	Pharmaceutical Compositions For the Prevention And Treatment Of Oxidant Injuries
64378	Ward, S.J.	5,081,122 14Jan92	Antiglaucoma Compositions Containing 4-Arylcarbonyl-1-(4-Morpholinyl-Lower-Alkyl)-1H-Indoles And Method of Use Thereof
71364	Christiansen et al	5,100,882 31Mar92	Antiandrogenic Sulfonylsteroidfurans
64206	Ward, S.	5,112,820 12May92	Anti-Glaucoma Compositions Containing 2- and 3-Aminoethyl-6-Arylcarbonyl- or 6-Phenylthio-2,3-Dihydrophthalo-(1,2,3-DE)-1,3,4 Benzoxazines...
61848	Dunlap et al	5,128,339 07Jul92	Proteolytic Enzyme Inhibition Method
62878	Berger et al	5,175,155 29Dec92	WIN 49596- Finasteride Method of Use and Compositions
62310	Mattes et al	5,183,813 02Feb93	Antiarrhythmic Agents
61785	Desai et al	5,187,173 16Feb93	Novel 2-Saccharinylmethyl And 4,5,6,7-Tetrahydro 2- Saccharinylmethyl Phosphates, Phosphonates and Phosphinates Useful as Proteolytic Enzyme Inhibitors and Compositions and Method of Use Thereof
64818	Tirrell et al	5,232,109 03Aug93	Double-Seal Stopper For Parenteral Bottle
55381	Dunlap et al	5,236,917 17Aug93	Novel Saccharin Derivatives Useful As Proteolytic Enzyme Inhibitors And Compositions And Method of Use Thereof
65740	Mallamo, J.	5,239,110 24Aug93	Phenylcyclohexanol Derivatives As Agents For Treating CNS Disorders
61838	Mallamo, J	5,240,935 31Aug93	Novel Substituted 2-Azabicyclo[2.2.2] Octane Derivatives And Compositions And Method of Use Thereof

**APPENDIX A**  
**UNITED STATES - Patents**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
61837	Diana, G.	5,242,924 07Sep93	Tetrazolyl-(Phenoxy and Phenoxyalkyl)- PiperidinylPyridazines As Antiviral Agents
61848	Dunlap et al	5,250,696 05Oct93	Novel 2-Saccharinylmethyl Aryl Carboxylates Useful as Proteolytic Enzyme Inhibitors and Compositions and Method of Use Thereof
63151	Washburn, W.	5,254,592 19Oct93	Multiply Substituted Phenols, Anilines and Pyridines - Immunomodulating Agents
63152	Washburn et al	5,258,407 02Nov93	3,4-Disubstituted Phenols - Immunomodulating Agents
61827	Johnson, R.	5,268,372 07Dec93	2,5-Benzodiazocine Antiarrhythmic Agents
62162	Dehaven-Hudkins et al	5,286,733 15Feb94	Novel Substituted 3-Piperidinealkanoates And Alkanones and Compositions And Method of Use Thereof
64352	Dehaven-Hudkins et al	5,290,789 01Mar94	Novel Penta And Tetrasubstituted Piperidiens And Compositnos and Method of Use Thereof
64534	Mallamo et al	5,290,796 01Mar94	Novel Substiuted 3-Piperidinealkanamines And Alkanamides and Compositons And Method of Use Thereof
64545	Kumar et al	5,292,736 08Mar94	Morpholinoalkylindenes As Analgesic and Antiglaucoma Agents
61823	Bacon et al	5,294,612 15Mar94	Novel 6-Heterocyclyl Pyrazoloy 3,4-d Pyrimidin-4-Ones And Compositons and Method of Use Thereof
61785	Desai et al	5,296,496 22Mar94	Novel 2-Saccharinylmethyl Phosphates, Phosphonates and Phosphinates Useful as Proteolytic Enzyme Inhibitors and Compositions and Method of Use Thereof
61346	Phillips et al	5,298,410 29Mar94	Lyophilized Formulation of Polyethylene Oxide Modified Proteins With Increased Shelf Life (as Amended)
61833	Magee, L.J.	5,305,658 26Apr94	Capsule Transfer Device

**APPENDIX A**  
**UNITED STATES - Patents**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
61848	Dunlap et al	5,306,818 26Apr94	Novel 2-Saccharinylmethyl Aryl Carboxylates Useful as Proteolytic Enzyme Inhibitors and Compositions and Method of Use Thereof
56529	Washburn et al	5,310,760 01May94	3,4-disubstituted Anilins - Immunomodulating Agents
63453	Stecher, V.	5,314,894 24May94	(S)-(+)-Hydroxychloroquine
61840	Eissenstat et al	5,330,992 19Jul94	1-Cyclopropyl-4-Pyridyl-Quinolinones
63158	Pagay et al	5,330,759 19Jul94	Enteric Coated Soft Capsules And Method of Preparation Thereof
61346	Phillips et al	5,334,382 02Aug94	Lyophilized Polyethylene Oxide Modified Protein and Polypeptide Complexes With Cyclodextrin
61841	Wentland, MP	5,334,595 02Aug94	Pyrazoloquinolones As Anticancer Agents
64299	Barrow et al	5,338,845 16Aug94	Novel Aspergillus Species, Cyclic Dimeric Dipeptide Derivative Substance P Antagonist Biosynthetic Products Thereof, and Process For Preparation
61862	Stetsko et al	5,340,589 23Aug94	Low Solubility Drug-Coated Bead Compositions
60934	Miller at al	5,346,917 13Sep94	Thioxanthenone Antitumor Agents
62308	Diana et al	5,349,068 20Sep94	1,2,4-Oxadiazolyl-Phenoxyalkylisoxazoles And Their Use As Antiviral Agents
61839	Eisssenstat et al	5,356,903 18Oct94	1-Cyclopropyl-4-Pyridyl-Quinolines
64365	Michne, W.	4,100,164 11Jul78	2,6-Methano-3-Benzazocines



**APPENDIX A**  
**UNITED STATES - Patents**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
64358	Bailey, D.M.	4,107,313 15Aug78	Antibacterial:(Alpha, Alpha Prime)-Bis-Y4-(Alkylamino)-1-Pyridinium Xylenes
64391	Lewis et al	4,119,628 10Oct78	Octahydro-3-Lower-Alkanoyl-2,5-Methanobenzoylquinoline-3-Carboxylate Esters
64391	Lewis et al	4,148,794 10Apr79	Octahydro-3-Lower-Alkanoyl-2,5-Methanobenzoylquinoline-3-Carboxylate Esters
63165	Christiansen, R.	4,160,027 03Jul79	Antifertility Agents; 2A-Cyano-4B-Methyl-4A,5A-Epoxyandrostanes
64365	Michne, W.F.	4,180,667 25Dec79	2,6-Methano-3-Benzazocines
64347	Bailey, D.M.	4,206,215 03Jun80	Antibacterial: Bis-Y4-(Alkylamino)-1-Pyridinium Alkanes
64360	Maxwell et al	4,207,982 17Jun80	C-Pak Flip-Top Container
64365	Michne, W.F.	4,239,890 16Dec80	Octahydro-5,5-Ethano And 3,5-Ethanobenzoylquinolines
64365	Michne, W.F.	4,255,579 10Mar81	2,6-Methano-3-Benzazocines
64365	Michne, W.F.	4,296,238 20Oct81	2,6-Methano-3-Benzazocines
63277	Leshner et al	4,297,360 27Oct81	6-Alkyl-5-Bipyridin-2,3-Diamines
60902	Leshner et al	4,361,568 30Nov82	
63230	Phillion, R.	4,374,149 15Feb83	Antihypertensives: 3-Alkyl-4-Hydroxyphenyl Ketones
63285	Bell et al	4,412,995 01Nov83	Tentacyclic Phenopyrozol Compound As Anti-inflammatory Agents
63182	Yu et al	4,415,547 15Nov83	Sustained Release Theophylline Formulation

**APPENDIX A**  
**UNITED STATES - Patents**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
63277	Leshner et al	4,420,617 13Dec83	6-Alkyl-5-Bipyridin-2,3-Diamines
63052	Leshner et al	4,448,780 15May84	N-R-N'-(5-(Pyridinyl)-2-Pyridinyl)Ureas
63049	Singh et al	4,451,469 29May84	1,2-Dihydro-4,6-Dialkyl-2-Oxo-Nicotinonitriles
63072	Leshner et al	4,463,008 31Jul84	2-Alkoxy-5-(Pyridinyl) Pyridines and Cardiotonic Use Thereof
63070	Wentland et al	4,499,091 12Feb85	
63060	Singh, B.	4,560,691 24Dec85	Cardiotonic Agents; 5-Aryl-1,6-Naphthyridin-2(1H)-Ones
63061	Leshner et al	4,567,186 28Jan86	5-Heteryl-1,6-Naphthyridin-2(1H)-Ones, Cardiotonic Use thereof and Intermedicates Therefor
63192	Bell, M.R.	4,634,776 06Jan87	2-Arylcarbonyl-1-Aminoalkyl-1H-Indoles
62868	Christiansen et al	4,684,636 04Aug87	Antiandrogenic Sulfonylsteroidopyrazoles And Process for Preparation
63068	Leshner et al	4,697,021 29Sep87	2-Y2-(Di-Lower-Alkylamino)-1-Propenyl-6-Methoxy-3-Pyridinecarbonitriles, Intermediates For Cardio-tonic Agents
63068	Leshner et al	4,716,170 29Dec87	2-Y2-(Di-Lower-Alkylamino)-1-Propenyl-6-Methoxy-3-Pyridinecarbonitriles, Intermediates For Cardio-tonic Agents
63192	Bell, M.R.	RE32761 04Oct88	2-Arylcarbonyl-1-Aminoalkyl-1H-Indoles
63100	Murray, D.G.	4778834 18Oct88	Dental Composite Resins Containing Durapatite
63225	Picciola et al	4791104 13Dec88	Dihydrobenzothiophene And Thiochromane Amminoalcohols
63178	Woodroff, E.A.	4820302 11Apr89	Bio and Blood Compatible Materials and Methods

**APPENDIX A**  
**UNITED STATES - Patents**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
63077	Bailey, D.M.	4829084 09May89	Method for treating Malignant Conditions
63101	Schlegel et al	4835180 30May89	Hydroxyphenylamino-Lower-Alkyl nitriles
63199	D'Ambra et al	4840950 20Jun89	1-Aminoalkyl-2-and 4-Arylcarbonyl-1H-Indoles
62609	Diana et al	4843087 27Jun89	Di-Heterocyclic Compounds And Their Use As Antiviral Agents
62609	Diana et al	4857539 15Aug89	Di-Heterocyclic Compounds And Their Use As Antiviral Agents
62609	Diana et al	4861791 29Aug89	Di-Heterocyclic Compounds And Their Use As Antiviral Agents
63083	Cebula, C.R.	4868305 19Sep89	Improvement In Amifloxacin Synthesis
63199	D'Ambra et al	4874761 17Oct89	1-Aminoalkyl-2-and 4-Arylcarbonyl-1H-Indoles
53620	Ogunbiyi et al	4877810 31Oct89	Protection of Heart Tissue From Reperfusion Injury
63192	Bell, M.R.	4885295 05Dec89	3-Arylcarbonyl-1-Aminoalkyl-1H-Indoles
63001	Bailey et al	4888352 19Dec89	Monoaryl-1H-Pyrazole-1-Alkanamide Antiarrhythmic Agents
62989	Bailey et al	4898880 06Feb90	Heterocyclic Amide Derivatives of Pyrazole-1-Alkanoic Acids
62609	Diana et al	4939267 03Jul90	Di-Heterocyclic Compounds And Their Use As Antiviral Agents
62795	D'Ambra et al	4939138 03Jul90	2- and 3-Aminomethyl-6-Arylcarbonyl-2,3-Dihydropyrroloyl,2,3-De -1,4-Benzoxazines
62609	Diana et al	4942241 17Jul90	Di-Heterocyclic Compounds And Their Use As Antiviral Agents

**APPENDIX A**  
**UNITED STATES - Patents**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
62609	Diana et al	4945164 31Jul90	Di-Heterocyclic Compounds And Their Use As Antiviral Agents
63092	Wentland, M.P.	4959363 25Sep90	Antiviral Agents; 4-Oxoquinoline-3- Carboxamides
60927	Leshner et al	4963561 16Oct90	
63986	Bradley et al	4965195 23Oct90	Interleukin-7
63200	Ward et al	4973587 27Nov90	3-Arylcarbonyl-1-Aminoalkyl-1H-Indole- Containing Antiglaucoma Compositions
63192	Bell, M.R.	4978664 18Dec90	3-Arylcarbonyl-1-Aminoalkyl-1H-Indoles
62609	Diana et al	5002960 26Mar91	Di-Heterocyclic Compounds And Their Use As Antiviral Agents
60927	Leshner et al	5010086 23Apr91	Imidazopyridines, Compositions and Use
60946	Cordes et al	5011985 30Apr91	Levo-Ciprofibrate
60951	Cordes et al	5011986 30Apr91	Dextro-Ciprofibrate
63192	Bell, M.R.	5013732 07May91	3-Arylcarbonyl-1-Aminoalkyl-1H-Indoles
63200	Ward et al	5013837 07May91	3-Arylcarbonyl-1-Aminoalkyl-1H-Indole- Containing Antiglaucoma Compositions
63988	Bradley et al	5032396 16Jul91	Use of Il-7 To Stimulate Platelet Production
62609	Diana et al	5051437 24Sep91	Di-Heterocyclic Compounds And Their Use As Antiviral Agents
62795	D'Ambra et al	5066803 19Nov91	2- And 3-Aminomethyl-6-Arylcarbonyl-2,3- Dihydropyrrolo (1,2,3-DE)-1,4-Benzoxazines
64304	D'Ambria T.E.	5068234 26Nov91	3-Arylcarbonyl-1-(C-Attached-N-Heteryl)-1H- Indoles

**APPENDIX A**  
**UNITED STATES - Patents**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
63019	Leshner et al	5075319 24Dec91	Pyridinyl-Quinolone Compounds, Their Preparation And Use
61907	Miller et al	5091410 25Feb92	Thioxanthenone' Antitumor Agents
61829	Johnsone t al	5098901 24Mar92	Imidazoyl,2-B Y2 Benzazepine And Pyrimidoyl,2-B Y2 Benzazepine Antirarrhythmic Agents
61830	Johnson et al	5106844 21apr92	Imidazoy2, 1-B Y3 Benzazepine And Pyrimidoy2, 1-B Y3 Benzazepine Antiarrhythmic Agents
62795	D'Ambra et al	5109135 28Apr92	2- Or 3-Aminomethyl-4-Amino-3,4-Dihydro-2H-1,4-Benzoxazine Intermediates
62609	Diana et al	5110821 05May92	1,3,4-Oxadiazolyl-Phenoxyalkylisoxazoles And Their Use As Antiviral Agents
63496	Mallamo et al	5134135 28Jul92	Antiandrogenic Sulfonylsteroidoxazoles
60869	Bacon, E. R.	5141931 25Aug92	5-Quinolinyipyridinones, Cardiotonic Compositions And Methods
63019	Leshner et al	5169853 08Dec92	Pyridinyl-Quinolone Compounds, Their Preparation And Use
62771	Diana et al	5175177 29Dec92	1,2,4- Oxadiazolyl-Phenoxyalkylisoxazoles And Their Use As Antiviral Agents
62609	Diana et al	5175178 29Dec92	1,2,4-Oxadiazolyl-Phenoxyalkylisoxazoles And Their Use As Antiviral Agents
61827	Johnson, R.E.	5206231 27Apr93	2,5-Benzodiazocine Antiarrhythmic Agents
57744	Gunther, W.H.H.	5208336 04May93	Selenomercyanines And Processes For Preparation And Methods Of Use And Compositions Thereof
62524	Weis et al	5214134 25May93	A Method of Linking Nucleosides With A Siloxane Bridge
61862	Stetsko et al	5223268 29Jun93	Low Solubility Drug-Coated Bead Compositions

**APPENDIX A**  
**UNITED STATES - Patents**

<b>Docket</b>	<b>Inventor(s)</b>	<b>Appln/Date</b>	<b>Title</b>
63989	Bradley et al	5229115 20Jul93	Immunotherapy With IL-7
62557	Weis et al	5245022 14Sep93	Nuclease Resistant Compounds
61866	Singh, J.	5256657 26Oct93	Succinamide Derivative Matrix-Metalloprotease Inhibitors
61902	Johnson, R.E.	5286752 15Feb94	Antiarrhythmic Diarylamidines
64117	Coughlin et al	5308843 03May94	Method of Inhibiting Mammalian Topoisomerase II and Malignant Cell Growth In Mammals With Substituted (S)-3-Methyl-7-Oxo-2,3-Dihydro-7H-Pyrido
64304	D'Ambra T.E.	5324737 28Jun94	3-Arylcarbonyl-1-(C-Attached-N-Heteryl)-1H-Indoles

**ADDITIONAL U.S. PAID-FOR-LIFE PATENTS**

<b>Patent No.</b>	<b>Grant Date</b>	<b>Title</b>
4,108,857	08/22/78	Analgesic Imidazolymethyl Methanobenzazocines
4,269,831	05/26/81	Topical Dermatological Method of Use of an Androsthenopyrazole
4,213,977	07/22/80	Pituitary-Adrenal Inhibiting Method (Nivazol)
4,085,144	04/18/78	Antibacterial N,N'-Bridged-Bis(2-Alkyl-2-Hydroxyethylamine) Dioxides
4,119,668	10/10/78	Antibacterial N,N'-Bridged-Bis(N,N-Substituted-2-Hydroxyalkaneammonium) Salts
4,140,860	02/20/79	Antibacterial Bridges-Bis-Hydroxyamide Dicarbanilates
4,149,000	04/10/79	Analgesic Antagonist 1,2,3,4,5,6-Hexahydro-3-alkyl-6-Methyl-11 (Eq-Hydroxy-11-Methyl-2,6-Methano-3-Benzazocines
4,205,171	05/27/80	Analgesic Aminomethanobenzazocines
4,127,577	11/28/78	Analgesic Aminomethanobenzazocines
4,053,636	10/11/77	Antibacterial Dichlorocyclopropylphenyl Bis Biguanides
4,217,354	08/12/80	Ketazocine Anesthetic Method of Use
4,294,840	10/12/81	Ketazocine Anesthetic Method of Use
4,200,655	04/29/80	Benzyl Alcohol Virucidal Process and Compositions Therefor
4,161,526	07/17/79	Zinc Slat Prevent Or Removal of Discoloration in Pyrithione, Pyrithione Salt and Dipyrithione Compositions
4,299,830	11/10/81	Analgesic 1,5-Methano-1,-Benzodiazocines-9-Amines
4,237,321	12/02/80	2,4,5-Trichlorophenol Process
4,374,132	02/15/83	Plasma Uric Acid Lowering Method (Azastene)
4,075,217	02/21/78	Conversion of 3-(Pyridinyl)-2-Cyclohexen-1-One to 3-(Pyridinyl)Anilines
4,111,946	09/05/78	Preparation of 3-(Pyridinyl)-2-Cyclohexen-1-Ones
4,127,583	11/28/78	Preparation of 3-(Pyridinyl)-2-Cyclohexen-1-Ones

**ADDITIONAL U.S. PAID-FOR-LIFE PATENTS**

<b>Patent No.</b>	<b>Grant Date</b>	<b>Title</b>
4,118,557	10/03/78	Cyclic Alkyldienyl N-(Lower-Alkyl)-3-(Pyridinyl)Anilinomethylenemalonates
4,104,385	08/01/78	Cyclic Alkyldienyl N-[6-(Amino)-3-Pyridazinyl]Anilinomethylehemalonates
4,055,588	10/25/77	Tetra-(Lower-Alkyl)3-(3-Nitrophenyl)-1,5-Pentanedione-1,2,4,5-Tetracarboxylates
4,086,233	04/25/78	4-(Substituted-Amino)-2-(Pyridinyl)Pyrimidine Derivatives
4,118,571	10/03/78	4-Acylamino-2-(Pyridinyl)-Pyrimidine Derivatives
RE 30,024	06/05/79	4-Amino (Or Hydrazino)-2-(Pyridinyl)Pyrimidines
4,107,167	08/15/78	Alkyl Alpha-[3-(Pyridinyl)Anilinomethylene]-Acetoacetates
4,137,227	01/30/79	1-Alkyl-1,4-Dihydro-4-Oxo-7-Triazinyl-3-Quinolincarboxylic Acids
4,053,475	10/11/77	N-[2-(Pyridinyl)-4-Pyrimidinyl]-Ureas Preparation
4,297,362	10/27/81	4-(3,4-diaminophenyl)Pyridine or Salts and Use Thereof As Cardiotonics
4,109,092	08/22/78	Preparation of 2-(Pyridinyl)-4-Pyrimidinamines
4,113,774	09/12/78	N-(Dichloroacetyl)Diamine Compounds and Process of Preparing Same
4,181,719	01/01/80	Phenyl N'-Acetylaminothioalkanoates
4,482,495	11/13/84	Mixed Anhydrides of N'-Acetylaminothioalkanoates
4,207,418	06/10/80	1,2-Ethanediamine Salts of Nalidixic Acid
4,317,827	03/02/82	4-[4(Or 3)-Acylaminophenyl]Pyridines and The IR Use as Cardiotonics
4,225,601	09/30/80	3-Hydroxy or Hydroxymethyl-5-(4-Pyridinyl)-2(1H)-Pyridinones, Useful As Cardiotonic Agents And Their Preparation
4,312,875	01/26/81	5-(Pyridinyl)-6-(Lower-Alkyl)-2(1H)-Pyridinones, 1,2-Dihydro-2-Oxo-5-(Pyridinyl)-6-(Lower-Alkyl)Niotinic Acids And...



**ADDITIONAL U.S. PAID-FOR-LIFE PATENTS**

<b>Patent No.</b>	<b>Grant Date</b>	<b>Title</b>
4,298,609	11/03/81	4,5-Dihydro-6-(4-Pyridinyl)-3-Pyridazinol And Salts, Their Preparation and Use as Blood Pressure Lowering Agents
4,304,775	12/08/81	3-Hydrazino-6-(Pyridinyl)Pyridazines And Cardiotonic Use Thereof
4,294,837	10/13/81	1,3-Dihydro-6-(Pyridinyl)-2H-Imidazo-[4,5-B]Pyridin-2-Ones And -Imidazo-[4,5-b]Pyridine-2-Thiones And Their Cardiotonic Use
4,264,603	04/28/81	5-(Pyridinyl)-1H-Pyrazolo[3,4-b]Pyridine-3-Amines, Their Use As Cardiotonics and Their Preparation
4,304,777	12/08/81	6-(Pyridinyl)-3(2H)-Pyridazinones And their Use As Cardiotonics
4,302,462	11/24/81	4-(Or 3)-(3,4-Dihydroxyphenyl)Pyridines, Their Cardiotonic Use and Cardiotonic Use of Their Methyl Ethers
4,246,420	01/20/81	Process For Preparing 3-(4-Pyridinyl)-2-Cyclohexene-1-One Oxime
4,304,776	12/08/81	4-Substituted-6-(Pyridinyl)-3(2H)-Pyridazinones and Their Use As Intermediates and Cardiotonics
4,271,168	06/02/81	Selected 3-Acylamino-5-[4(Or 3)Pyridinyl]-2(1H)-Pyridinones
4,297,363	10/27/81	2-Amino-3(4 or 5)-(Pyridinyl) Phenols And Their Use As Cardiotonics
4,265,895	05/05/81	1,2-Dihydro-5-Pyridinyl-3H-Pyrazolo[3,4-b]Pyridin-3-Ones And Their Use As Cardiotonics
4,276,293	06/30/81	6-(Pyridinyl)-3H-Imidazo[4,5-B]Pyridines
4,264,612	04/28/81	Lower-Alkyl 1-Halo-5-(Pyridinyl)Nicotinates, Their Preparation And Use As Cardiotonics
4,294,836	10/13/81	1,3-Dihydro-6-(Pyridinyl)-2H-Imidazol-[4,5-B]Pyridin-2-Ones and -Imidazol-[4,5-B]Pyridine-2-Thiones And Their Cardiotonic Use
4,391,811	07/05/83	2-Amino-6-(Pyridinyl)-3H-Imidazo-[4,5-B]Pyridines And Their Cardiotonic Use

**ADDITIONAL U.S. PAID-FOR-LIFE PATENTS**

<b>Patent No.</b>	<b>Grant Date</b>	<b>Title</b>
4,305,943	12/15/81	4-Amino-6-(Pyridinyl)-3(2H)-Pyridazinones And Their Use As Cardiotonics
4,310,531	01/12/82	5-(Pyridinyl)-Benzoxazol-2(3H)-Ones And Their Use As Cardiotonics
4,335,131	06/15/82	Amrinone-N-Glucuronide, Salts and Cardiotonic Use Thereof
4,395,423	07/26/83	Polycyclic Cyanoketones
4,171,378	10/15/79	Aryl Substituted Diketones
4,093,736	06/06/78	Ethylenedioxyphenyl Substituted Aliphatic Diketones
4,189,500	02/19/80	Aryl Substituted Diketones
4,182,729	01/08/80	Arylvinyl Cyclopropyl Ketones
4,166,074	08/28/79	Arylethyl (or Vinyl) Cyclopropyl Carbinols
4,227,015	10/07/80	Substitued Phenylvinyl Cyclopropyl; Ketones
4,275,201	06/23/81	Aryl Substituted Diketones
4,125,541	11/14/78	Aryl Substitued Ketones
4,125,714	11/14/78	Aryl Substituted Cycloalkanones
4,133,959	01/09/79	Aryloxyalkyl Diketones
4,171,376	10/16/79	Aryloxyalkyl Keto-Esters
4,182,761	01/08/80	Acyloxy-Substiuted Aryloxyalkyl Diketones
4,198,436	04/15/80	Dialkylamino- and Dialkylaminoalkoxy-Substitued Aryloxyalkyl Diketones
4,182,727	01/08/80	Sulfo- And Aminosulfonyl-Substitued Aryloxyalkyl Diketones, Related Compounds and Intermediates
4,246,284	01/20/81	Aminosulfonyl-Substitued Aryloxyalkyl Diketones
4,179,567	12/18/79	2-Aryltropane Compounds
4,214,084	07/22/80	2-Aryltropane Compounds

**ADDITIONAL U.S. PAID-FOR-LIFE PATENTS**

<b>Patent No.</b>	<b>Grant Date</b>	<b>Title</b>
4,281,130	07/28/81	Lower-Alkyl 4,6,7,8, 8A, 9-Hexahydro-6,9-Ethanothieno[3,2-F]-Indolizine-10-Carboxylate
4,233,448	11/11/80	3-Methoxycarbonyl-2-(2-Thienyl)-8-Azabicyclo[3.2.1.]Octane-8-Acetamide and Salts Thereof
4,233,449	11/11/80	1-(8-Methyl-2-Phenyl (Or Thienyl)-8-Azabicyclo[3.2.1.]Octan-3-Yl)Ethanone
4,153,719	05/08/79	Aromatic Diketones
4,208,425	06/17/80	Novel Diketones
4,171,371	10/16/79	Diketones
4,096,280	06/20/78	Arylenedioxy-Bis-Diketones
4,150,134	04/17/79	Aminoalkoxy Substitued 9-(Aryl or Aralkyl)-Acridines
4,244,954	01/13/81	Acricine Compounds and Method of Combating Viruses With Them
4,171,365	10/16/79	Antiviral Aryloxyalkylpyrazoles
4,209,526	06/24/80	Aryloxyalkylpyrazoles
4,261,928	04/14/81	2-Benzoyl-8-(2-Chloro-4-Methoxyphenoxy)-1-Phenyl-1-Octane
4,234,725	11/18/80	4-[6-(2-Chloro-4-Methoxyphenoxy)Hexyl]-3,5-Diethyl-1-[4-(4-Morpholinyl)-1-Oxobutyl]-1H-Pyrazole
4,232,161	11/04/80	4-[6-(2-Chloro-4-Methoxyphenoxy)Hexyl]-3,5-Diethyl-1-(2-Pyridinyl)-1H-Pyrazole
4,268,678	05/19/81	4-(Arylaliphatic)Isoxazoles
4,072,692	02/07/78	Trans-4-(8-Hydroxyoctyl)-5-Octyl-1,3-Dithiolane-2-Thione
4,157,349	06/05/79	Dehydrohalogenation Process
4,182,759	01/08/80	Arylalkyl and Aryloxyalkyl Phosphonates
4,217,346	08/12/80	Arylalkyl and Aryloxyalkyl Phosphonates

**ADDITIONAL U.S. PAID-FOR-LIFE PATENTS**

<b>Patent No.</b>	<b>Grant Date</b>	<b>Title</b>
4,062,864	12/13/77	3-Hydroxy Carbazole derivatives
4,224,335	09/23/80	Method of Treating Congestive Heart Failure With 3-Amino-Tetrahydrocarbozoles
4,172,834	10/30/79	3-Amino-Tetrahydrocarbazoles
4,058,532	11/15/77	1-Phenyl-3,4-Dihydrocarbostyrils
4,052,382	10/04/77	1-Phenyl-3-Azacarbocyclic-Yreas
4,205,185	05/27/80	A Process For Preparing 4-Hydroxyphenylglycine
4,174,402	11/13/79	A Method For The Prophylaxis of SRS-A-Induced Symptoms
4,301,283	11/17/81	Process for Preparing 2-Oxo-Dihydrobenzo(D) (1,3)-Oxazines
4,112,105	09/05/78	Anti-Inflammatory 3-(Substitued-Amino)-2,1-Benzisothiazoles
4,152,518	05/01/79	Halogenated Thiobenzamides
4,169,108	09/25/79	5 (or 6)-[(Substitued Maino)Alkyl]-2,3-Naphthalenediols As Cardiotonic Agents
4,327,022	04/27/82	Heterocyclic Alkyl Naphthols As Cardiotonic Agents
4,097,935	07/04/78	Hydroxylapatite Ceramic
4,207,306	06/10/80	Process for Producing Polycrystalline Ceramic Oxides
4,327,224	04/27/82	Alpha-[(Alkylamino)Alkyl]-4-Hydroxy-3-Alkylthio)Benzenemethanols, Derivates Thereof And Intermediates Therefor
4,124,722	11/07/78	Therapeutic Method of Controlling Tachycardia
4,195,366	04/01/80	Whitlockite Ceramic
4,312,821	01/26/82	Ceramic Forming Process
4,065,471	12/27/77	N-(4-Amino-2-Butynyl) Imides
4,069,337	01/17/78	2-Substitued-Indole-1-Lower-Alkane-Carboxamides Having Anti-Secretory or Anti-Ulcer Activity

**ADDITIONAL U.S. PAID-FOR-LIFE PATENTS**

<b>Patent No.</b>	<b>Grant Date</b>	<b>Title</b>
4,084,051	04/11/78	Pyrrole-2-Carboxamides
4,160,862	07/10/79	1-Acyl-3-(Amino-Lower-Alkyl)Indoles
4,098,797	07/04/78	Cyclopenta [C] Pyrrole Derivatives
4,126,620	11/21/78	Cyclopenta [C] Pyrrole Derivatives
4,140,854	02/20/79	Cyclopenta [C] Pyrrole Derivatives
4,196,296	04/01/80	Cyclopenta [C] Pyrrole Derivatives
4,239,687	12/16/79	Cyclopenta [C] Pyrrole Derivatives
4,220,763	09/02/80	Cyclopenta [C] Pyrrole Derivatives
4,273,713	06/16/81	Phenyl and Lower Alkyl Substituted Pyrrole-3-Acrylonitriles
4,138,405	02/06/79	1-(Arylamino)-And 1-(Arylimino)-Pyrroles
4,163,015	07/31/79	1-(Arylamino)Pyrroles
4,172,835	10/30/79	1-(Phenylamino)Pyrrole
4,105,766	08/08/78	4,5-Dihydro-5-Oxopyrazolo[1,5-A]Quinazoline-3-Carboxylic Acid Derivatives
4,126,616	11/21/78	N-Propylnorapomorphine Diesters
4,080,380	03/21/78	2-Naphthyl-Lower-Alkylamines
4,069,256	01/17/78	Anti-Inflammatory Phenyl-Lower-Alkylamines
4,216,326	08/05/80	Intermediates For Preparing Anti-Inflammatory Phenyl-Lower-Alkylamines
4,308,382	12/29/81	4-[[3-[Alpha-Aminobenzyl]Phenyl]Methyl]Morpholine and 4-[[3-Benzoyl-Phenyl]Ethyl]Morpholine
4,396,609	08/02/83	Aminocyclitol Antibiotics, Pharmaceutical Compositions and Method of Using Same
4,162,361	07/24/79	Morphine/Apomorphine Rearrangement Process

**ADDITIONAL U.S. PAID-FOR-LIFE PATENTS**

<b>Patent No.</b>	<b>Grant Date</b>	<b>Title</b>
4,215,137	07/29/80	Method of Alleviating Diseases By Cell-Mediated Immune Stimulation and Compositions Useful Therefor
4,208,523	06/17/80	11-Lower-Alkyl, 11-Phenyl-Lower-Alkyl- And 11-Cycloalkyl-Lower-alkyl-Hexahydro-2,6-Methano-3-Benzazocines
4,248,784	02/03/81	Pyrrole-3-Acetamides
4,105,764	08/08/78	4,5-Dihydro-5-Oxopyrazolo[1,5-A]Quinazoline-3-Carboxamides
4,202,984	05/13/80	Beta-(Hexahydro-2,6-Methano-3-Benzazocin-11-yl)Propionic Acids, Esters and Amides
4,214,085	07/22/80	11-[3-Oxo-Omega-(2- and 3-Furyl)-Lower-Alkyl]Hexahydro-2,6-Methano-3-Benzazocines
4,228,286	10/14/80	Intermediates For 11-[3-Oxo-Omega-(2- and 3-Furyl)-Lower-Alkyl]Hexa-Hydro-2,6-Methano-3-Benzazocines
4,202,983	05/13/80	11-(Lower-Alkoxy- And Lower-Alkylthio-3-Oxo-Lower-Alkyl)-Hexahydro-2,6-Methano-Benzazocines
Des. 263,559	03/30/82	Pharmaceutical Package
4,288,547	09/08/81	Antibiotics of the Gentamicin Class
4,387,219	06/07/83	2-Hydroxy Gentamicin compounds
4,304,911	12/08/81	Anti-Asthmatic, Anti-Allergic, Anti-Cholinergic, Bronchodilator and Anti-Inflammatory 1-[(Benzoylphenyl)-lower-Alkyl]Piperidines
4,182,895	01/08/80	1-Amino-Lower-Alkyl-3,4-Diphenyl-1H-Pyrazoles and Processes For Their Preparation
4,062,954	12/13/77	Pregnancy Disrupting Method of Use Of Trilostane
4,161,598	07/17/79	
4,257,952	03/24/81	
Des. 349,648	08/16/94	
4,254,871	03/10/81	
4,362,000	12/07/82	




61859/J-B  
UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

DATE: 07/28/93  
TO:

N08B

STERLING WINTHROP INC.  
IMRE (JIM) BALOGH  
PATENT DEPARTMENT  
9 GREAT VALLEY PKWY  
MALVERN, PENNSYLVANIA 19355



UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE U.S. PATENT AND TRADEMARK OFFICE ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT ASSIGNMENT PROCESSING SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT BRANCH, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231

ASSIGNOR:  
DOLLE, ROLAND E.

DOC DATE: 06/01/93

ASSIGNOR:  
HOYER, DENTON W.

DOC DATE: 06/01/93

ASSIGNOR:  
ROSS, TINA M.

DOC DATE: 06/01/93

ASSIGNOR:  
RINKER, JAMES M.

DOC DATE: 06/01/93

ASSIGNOR:  
SCHMIDT, STANLEY J.

DOC DATE: 06/01/93


ASSIGNOR:  
ATOR, MARK A.

DOC DATE: 06/01/93

RECORDATION DATE: 06/08/93    NUMBER OF PAGES 006    REEL/FRAME 6590/0643

DIGEST : ASSIGNMENT OF ASSIGNORS INTEREST

ASSIGNEE:  
STERLING WINTHROP INC.  
90 PARK AVENUE  
NEW YORK, NEW YORK 10016



6590/0643 PAGE 0002


SERIAL NUMBER 8-073914  
PATENT NUMBER

FILING DATE 06/08/93  
ISSUE DATE 00/00/00

*Nicole Scott*

EXAMINER/PARALEGAL  
ASSIGNMENT BRANCH  
ASSIGNMENT/CERTIFICATION SERVICES DIVISION





08/073914 A/D

PTO-1595  
1-51-92

RECORDATION FORM COVER SHEET  
PATENTS ONLY

U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Docket No. 61859

To the Honorable Commissioner of Patents and Trademarks, Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):  
Roland E. Dolle Stanley J. Schmidt  
Denton W. Hoyer Mark A. Ator  
Tina Morgan Ross  
James M. Rinker

2. Name and address of receiving party(ies):  
Name:

Sterling Winthrop Inc.  
90 Park Avenue  
New York, NY 10016

Additional name(s) of conveying party(ies) attached? [ ] yes [ X ] no

3. Nature of Conveyance: 19  
[ X ] Assignment [ ] Merger  
[ ] Security Agreement [ ] Change of Name  
[ ] Other  
Execution Date: June 1, 1993

Additional name(s) & address(es) attached? [ ] Yes [ X ] No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)

B. Patent No.(s)

Additional numbers attached? [ ] Yes [ ] No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Sterling Winthrop Inc.  
Internal Address: Patent Department

Street Address: 9 Great Valley Pkwy

City: Malvern State: PA ZIP 19355

6. Total number of applications and patents involved: [ 1 ]

7. Total fee (37 CFR 3.41): .....\$ 40.00

Please charge deposit account number: 19-4325

8. Deposit account number: 19-4325

(Attach duplicate copy of this page)

P 30226 06/18/93 08073914 DO NOT USE THIS SPACE 19-4325-030 581 40.00CH

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document

Imre (Jim) Balogh

Name of Person Signing

Signature

June 8/93 Date

OMB No. 0651-0011 (exp. 4/94)

10 Total number of pages comprising cover sheet: [6]

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

93368375

Commissioner of Patents and Trademarks  
Box Assignments  
Washington, D.C. 20231

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project. (0651-0011), Washington, D.C. 20503

REF 6590 FRAME 643

## JOINT ASSIGNMENT

For good and valuable consideration received, we confirm that we have sold and assigned and do hereby sell and assign to Sterling Winthrop Inc., a Delaware Corporation having a place of business at New York, New York, its successors and assigns, the entire right, title, interest and priority rights in and to all of my inventions, discoveries and improvements disclosed in an application for Letters Patent for

PYRIDAZINES AS INTERLEUKIN-1 $\beta$ -CONVERTING ENZYME  
INHIBITORS

executed by Roland E. Dolle the 1 day of June, 1993  
executed by Denton W. Hoyer the 1 day of June, 1993  
executed by Tina Morgan Ross the 1 day of June, 1993  
executed by James M. Rinker the 1 day of June, 1993  
executed by Stanley J. Schmidt the 1 day of June, 1993  
executed by Mark A. Ator the 1 day of June, 1993

- ☒ about to be filed  
☐ already filed as USSN \_\_\_\_\_

in the United States Patent and Trademark Office, together with said application, applications corresponding thereto in whole or in part in all other countries, and all right, title and interest in an to Letters Patent and similar protective rights, granted on said applications, as well as the right to claim any applicable priority rights arising from said applications under the terms of any applicable conventions, treaties, statutes or regulations, said applications to be filed and issued in the name of Sterling Winthrop Inc., or its designee; and we agree to execute such documents as in the judgment of Sterling Winthrop Inc. may be necessary to obtain any such patents and similar protective rights and vest and maintain the title thereto in Sterling Winthrop Inc. or its designee; and we further agree that, upon request, but without expense to us, we shall furnish to Sterling Winthrop Inc. or its designee any data, information, exhibits, memoranda, or other evidence in my possession relating to any of said inventions, discoveries or improvements and shall testify in any ex parte or inter partes legal or administrative proceedings relating to any of said inventions, discoveries, improvements, applications, patents or similar

REF 6590 FRAME 644

protective rights; and we authorize and request issuance of all Letters Patent and similar protective rights that may be granted on any of said applications, to the extent that and in such manner as such issuance shall be requested by Sterling Winthrop Inc. or its designee. This document shall be governed, construed and interpreted in all respects in accordance with the laws of the State of New York, USA.

In testimony whereof I have hereunto set my hand this 1st day of June, 1993.


Roland E. Dolle  
Roland E. Dolle

Signed in the presence of Bernice H. Rybacki  
Witness

COMMONWEALTH OF PENNSYLVANIA )  
COUNTY OF CHESTER ) SS:

On this 1st day of June, 1993 personally appeared before me the above-named **Roland E. Dolle** to me known and known to me to be the person described in and who executed the foregoing instrument and acknowledged the same to be his act and deed in and for the purposes set forth in said instrument.

Joan M. Czajkowski  
Notary Public



REF 6590 FRAME 645

In testimony whereof I have hereunto set my hand this 1<sup>st</sup> day of June, 1993.


Denton W. Hoyer  
Denton W. Hoyer

Signed in the presence of: Bernie H. Rybacki  
Witness

COMMONWEALTH OF PENNSYLVANIA )  
COUNTY OF CHESTER ) SS:

On this 1<sup>st</sup> day of June, 1993 personally appeared before me the above-named **Denton W. Hoyer** to me known and known to me to be the person described in and who executed the foregoing instrument and acknowledged the same to be his act and deed in and for the purposes set forth in said instrument.

Joan M. Czajkowski  
Notary Public



In testimony whereof I have hereunto set my hand this 1<sup>st</sup> day of June, 1993.


Tina Morgan Ross  
Tina Morgan Ross

Signed in the presence of: Bernie H. Rybacki  
Witness

COMMONWEALTH OF PENNSYLVANIA )  
COUNTY OF CHESTER ) SS:

On this 1<sup>st</sup> day of June, 1993 personally appeared before me the above-named **Tina Morgan Ross** to me known and known to me to be the person described in and who executed the foregoing instrument and acknowledged the same to be his act and deed in and for the purposes set forth in said instrument.

Joan M. Czajkowski  
Notary Public



REC-6590 FRANK 646

In testimony whereof I have hereunto set my hand this 1st day of June, 1993.


James M. Rinker  
James M. Rinker

Signed in the presence of: Bernice H. Rybacki  
Witness

COMMONWEALTH OF PENNSYLVANIA )  
COUNTY OF CHESTER ) SS:

On this 1st day of June, 1993 personally appeared before me the above-named **James M. Rinker** to me known and known to me to be the person described in and who executed the foregoing instrument and acknowledged the same to be his act and deed in and for the purposes set forth in said instrument.

Joan M. Czajkowski  
Notary Public



In testimony whereof I have hereunto set my hand this 1st day of June, 1993.


Stanley J. Schmidt  
Stanley J. Schmidt

Signed in the presence of: Bernice H. Rybacki  
Witness

COMMONWEALTH OF PENNSYLVANIA )  
COUNTY OF CHESTER ) SS:

On this 1st day of June, 1993 personally appeared before me the above-named **Stanley J. Schmidt** to me known and known to me to be the person described in and who executed the foregoing instrument and acknowledged the same to be his act and deed in and for the purposes set forth in said instrument.

Joan M. Czajkowski  
Notary Public



In testimony whereof I have hereunto set my hand this 1<sup>st</sup> day of JUNE, 1993.


Mark A. Ator  
Mark A. Ator

Signed in the presence of: Bernice H. Rybacki  
Witness

COMMONWEALTH OF PENNSYLVANIA )  
COUNTY OF CHESTER ) SS:

On this 1<sup>st</sup> day of June, 1993 personally appeared before me the above-named **Mark A. Ator** to me known and known to me to be the person described in and who executed the foregoing instrument and acknowledged the same to be his act and deed in and for the purposes set forth in said instrument.

Joan M. Czajkowski  
Notary Public



REEL 6590 FRAME 648

JUN -8 93

RECORDED  
PATENT AND TRADEMARK  
OFFICE

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**